I believe that the development of an effective totally bioabsorbable atrial defect occluder device would be next in the evolution of ASD occluder technology. As we perform these procedures in children whose lifespans 80 or 90 years, we are closing the door to entry of the left atrium for a number of these children as they enter adulthood, and may acquire structural cardiac lesions that require left atrial entry, such as arrhythmia ablation, LAA closure, MV interventions. A bioabsorbable device for ASD closure is of paramount importance to better cardiac care.
Prof. Dr. Lee Benson, Pediatric cardiologist, Toronto
The supporting structure of current transcatheter ASD closure device designs is the part that can lead to late perforations or erosions. A framework that dissolves when no longer needed might reduce the risk of some of the late complications, and should be a significant advance to ASD treatment.
Prof. Dr. Larry Latson, Pediatric cardiologist, Hollywood, FL
The concept of bioresorbability is incredibly attractive. While we have been performing transcatheter ASD closures for over two decades, we have always left behind a device which changed both the electrical and mechanical properties of the septum. In a new world where a variety of L heart procedures require the passage of large tubes across that septum, the importance of having only native tissue cannot be overstated.
Prof. Dr. Robert J. Sommer, Interventional cardiologist, New York